Which has better valuation & earnings, VSTM or MNKD?

MannKind has higher revenue and earnings than Verastem. MannKind is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 10.43 -$209.47M -$2.70 N/A MannKind $348.97M 3.00 $5.86M -$0.07 N/A

Is VSTM or MNKD more profitable?

MannKind has a net margin of -6.63% compared to Verastem's net margin of -391.17%. MannKind's return on equity of -11.21% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -391.17% -486.40% -91.56% MannKind -6.63% -11.21% -3.92%

Does the media prefer VSTM or MNKD?

In the previous week, MannKind had 6 more articles in the media than Verastem. MarketBeat recorded 8 mentions for MannKind and 2 mentions for Verastem. MannKind's average media sentiment score of 0.74 beat Verastem's score of -0.54 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative MannKind 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, VSTM or ZBIO?

Verastem has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 10.43 -$209.47M -$2.70 N/A Zenas BioPharma $10M 111.17 -$377.74M -$8.47 N/A

Is VSTM or ZBIO more profitable?

Zenas BioPharma has a net margin of 0.00% compared to Verastem's net margin of -391.17%. Zenas BioPharma's return on equity of -99.99% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -391.17% -486.40% -91.56% Zenas BioPharma N/A -99.99% -58.06%

Does the media prefer VSTM or ZBIO?

In the previous week, Zenas BioPharma had 1 more articles in the media than Verastem. MarketBeat recorded 3 mentions for Zenas BioPharma and 2 mentions for Verastem. Zenas BioPharma's average media sentiment score of 0.45 beat Verastem's score of -0.54 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, VSTM or OPK?

Verastem has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 10.43 -$209.47M -$2.70 N/A OPKO Health $606.90M 1.78 -$225.68M -$0.27 N/A

Is VSTM or OPK more profitable?

OPKO Health has a net margin of -36.63% compared to Verastem's net margin of -391.17%. OPKO Health's return on equity of -16.78% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -391.17% -486.40% -91.56% OPKO Health -36.63% -16.78% -10.98%

Does the media refer more to VSTM or OPK?

In the previous week, OPKO Health had 2 more articles in the media than Verastem. MarketBeat recorded 4 mentions for OPKO Health and 2 mentions for Verastem. OPKO Health's average media sentiment score of 1.32 beat Verastem's score of -0.54 indicating that OPKO Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative OPKO Health 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LXRX or VSTM?

In the previous week, Lexicon Pharmaceuticals and Lexicon Pharmaceuticals both had 2 articles in the media. Lexicon Pharmaceuticals' average media sentiment score of 0.00 beat Verastem's score of -0.54 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verastem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Which has preferable earnings & valuation, GERN or VSTM?

Geron has higher revenue and earnings than Verastem. Geron is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Geron $183.88M 3.94 -$83.50M -$0.11 N/A Verastem $30.91M 10.43 -$209.47M -$2.70 N/A

Is GERN or VSTM more profitable?

Geron has a net margin of -35.48% compared to Verastem's net margin of -391.17%. Geron's return on equity of -23.31% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Geron -35.48% -23.31% -10.08% Verastem -391.17% -486.40% -91.56%

Does the media prefer GERN or VSTM?

In the previous week, Geron and Geron both had 2 articles in the media. Geron's average media sentiment score of -0.20 beat Verastem's score of -0.54 indicating that Geron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verastem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Verastem (VSTM) Competitors

$3.67 -0.04 (-1.08%)

Closing price 04:00 PM Eastern

Extended Trading

$3.69 +0.02 (+0.52%)

As of 07:29 PM Eastern

Compare

VSTM vs. MNKD, ZBIO, OPK, LXRX, and GERN

Should you buy Verastem stock or one of its competitors? MarketBeat compares Verastem with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Verastem include MannKind (MNKD), Zenas BioPharma (ZBIO), OPKO Health (OPK), Lexicon Pharmaceuticals (LXRX), and Geron (GERN). These companies are all part of the "biotechnology" industry.

How does Verastem compare to MannKind?

Verastem (NASDAQ:VSTM) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Verastem has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, MannKind has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

MannKind has a net margin of -6.63% compared to Verastem's net margin of -391.17%. MannKind's return on equity of -11.21% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
MannKind	-6.63%	-11.21%	-3.92%

In the previous week, MannKind had 6 more articles in the media than Verastem. MarketBeat recorded 8 mentions for MannKind and 2 mentions for Verastem. MannKind's average media sentiment score of 0.74 beat Verastem's score of -0.54 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
MannKind	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.4% of Verastem shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 1.9% of Verastem shares are held by company insiders. Comparatively, 2.6% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MannKind has higher revenue and earnings than Verastem. MannKind is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	10.43	-$209.47M	-$2.70	N/A
MannKind	$348.97M	3.00	$5.86M	-$0.07	N/A

Verastem currently has a consensus target price of $15.60, indicating a potential upside of 325.07%. MannKind has a consensus target price of $8.97, indicating a potential upside of 164.56%. Given Verastem's stronger consensus rating and higher possible upside, equities analysts clearly believe Verastem is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

MannKind beats Verastem on 10 of the 16 factors compared between the two stocks.

How does Verastem compare to Zenas BioPharma?

Verastem (NASDAQ:VSTM) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Verastem has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	10.43	-$209.47M	-$2.70	N/A
Zenas BioPharma	$10M	111.17	-$377.74M	-$8.47	N/A

88.4% of Verastem shares are owned by institutional investors. 1.9% of Verastem shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Verastem has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, indicating that its share price is 171% less volatile than the broader market.

In the previous week, Zenas BioPharma had 1 more articles in the media than Verastem. MarketBeat recorded 3 mentions for Zenas BioPharma and 2 mentions for Verastem. Zenas BioPharma's average media sentiment score of 0.45 beat Verastem's score of -0.54 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zenas BioPharma has a net margin of 0.00% compared to Verastem's net margin of -391.17%. Zenas BioPharma's return on equity of -99.99% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
Zenas BioPharma	N/A	-99.99%	-58.06%

Verastem currently has a consensus target price of $15.60, suggesting a potential upside of 325.07%. Zenas BioPharma has a consensus target price of $44.29, suggesting a potential upside of 151.48%. Given Verastem's stronger consensus rating and higher possible upside, equities research analysts clearly believe Verastem is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

Verastem beats Zenas BioPharma on 9 of the 16 factors compared between the two stocks.

How does Verastem compare to OPKO Health?

Verastem (NASDAQ:VSTM) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, OPKO Health had 2 more articles in the media than Verastem. MarketBeat recorded 4 mentions for OPKO Health and 2 mentions for Verastem. OPKO Health's average media sentiment score of 1.32 beat Verastem's score of -0.54 indicating that OPKO Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
OPKO Health	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.4% of Verastem shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 1.9% of Verastem shares are held by company insiders. Comparatively, 49.7% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

OPKO Health has a net margin of -36.63% compared to Verastem's net margin of -391.17%. OPKO Health's return on equity of -16.78% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
OPKO Health	-36.63%	-16.78%	-10.98%

Verastem has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	10.43	-$209.47M	-$2.70	N/A
OPKO Health	$606.90M	1.78	-$225.68M	-$0.27	N/A

Verastem currently has a consensus price target of $15.60, suggesting a potential upside of 325.07%. OPKO Health has a consensus price target of $1.55, suggesting a potential upside of 8.39%. Given Verastem's stronger consensus rating and higher possible upside, equities research analysts plainly believe Verastem is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

Verastem has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Summary

OPKO Health beats Verastem on 9 of the 16 factors compared between the two stocks.

How does Verastem compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of Verastem shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Lexicon Pharmaceuticals currently has a consensus target price of $4.55, suggesting a potential upside of 142.02%. Verastem has a consensus target price of $15.60, suggesting a potential upside of 325.07%. Given Verastem's stronger consensus rating and higher probable upside, analysts clearly believe Verastem is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Lexicon Pharmaceuticals has higher revenue and earnings than Verastem. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	16.77	-$50.34M	-$0.07	N/A
Verastem	$30.91M	10.43	-$209.47M	-$2.70	N/A

In the previous week, Lexicon Pharmaceuticals and Lexicon Pharmaceuticals both had 2 articles in the media. Lexicon Pharmaceuticals' average media sentiment score of 0.00 beat Verastem's score of -0.54 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verastem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Lexicon Pharmaceuticals has a net margin of -37.46% compared to Verastem's net margin of -391.17%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Verastem	-391.17%	-486.40%	-91.56%

Lexicon Pharmaceuticals has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Verastem has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Summary

Lexicon Pharmaceuticals beats Verastem on 10 of the 16 factors compared between the two stocks.

How does Verastem compare to Geron?

Geron (NASDAQ:GERN) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Geron has higher revenue and earnings than Verastem. Geron is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	3.94	-$83.50M	-$0.11	N/A
Verastem	$30.91M	10.43	-$209.47M	-$2.70	N/A

In the previous week, Geron and Geron both had 2 articles in the media. Geron's average media sentiment score of -0.20 beat Verastem's score of -0.54 indicating that Geron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verastem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Geron has a net margin of -35.48% compared to Verastem's net margin of -391.17%. Geron's return on equity of -23.31% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
Verastem	-391.17%	-486.40%	-91.56%

Geron presently has a consensus price target of $2.50, suggesting a potential upside of 121.24%. Verastem has a consensus price target of $15.60, suggesting a potential upside of 325.07%. Given Verastem's stronger consensus rating and higher probable upside, analysts plainly believe Verastem is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

73.7% of Geron shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 1.7% of Geron shares are owned by insiders. Comparatively, 1.9% of Verastem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Geron has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Verastem has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Summary

Geron and Verastem tied by winning 8 of the 16 factors compared between the two stocks.

Get Verastem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VSTM vs. The Competition

Export

Metric	Verastem	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$326.01M	$3.30B	$6.43B	$12.05B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	-1.36	18.93	23.75	23.75
Price / Sales	10.43	173.93	479.99	83.74
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	4.96	8.04	10.28	6.78
Net Income	-$209.47M	$23.89M	$3.57B	$337.51M
7 Day Performance	-12.41%	-5.97%	-1.43%	-2.72%
1 Month Performance	-24.95%	2.78%	3.27%	1.87%
1 Year Performance	-42.83%	36.26%	23.37%	26.61%

Verastem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VSTM Verastem	2.6557 of 5 stars	$3.67 -1.1%	$15.60 +325.1%	-42.2%	$326.01M	$30.91M	N/A	50	Gap Up
MNKD MannKind	4.1567 of 5 stars	$3.53 -6.4%	$8.97 +154.1%	-22.4%	$1.16B	$348.97M	N/A	400	Analyst Upgrade
ZBIO Zenas BioPharma	3.6793 of 5 stars	$18.17 -1.3%	$44.29 +143.7%	+57.1%	$1.16B	N/A	N/A	N/A
OPK OPKO Health	2.3143 of 5 stars	$1.40 -4.1%	$1.55 +10.7%	+5.9%	$1.10B	$581.12M	N/A	1,373	News Coverage Analyst Upgrade Gap Down
LXRX Lexicon Pharmaceuticals	1.6541 of 5 stars	$2.07 -5.0%	$4.55 +119.8%	+148.1%	$968.35M	$49.80M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VSTM) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verastem (VSTM) Competitors

VSTM vs. MNKD, ZBIO, OPK, LXRX, and GERN

How does Verastem compare to MannKind?

Summary

How does Verastem compare to Zenas BioPharma?

Summary

How does Verastem compare to OPKO Health?

Summary

How does Verastem compare to Lexicon Pharmaceuticals?

Summary

How does Verastem compare to Geron?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM vs. The Competition

Verastem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verastem (VSTM) Competitors

VSTM vs. MNKD, ZBIO, OPK, LXRX, and GERN

How does Verastem compare to MannKind?

Which has more risk & volatility, VSTM or MNKD?

Is VSTM or MNKD more profitable?

Does the media prefer VSTM or MNKD?

Do insiders and institutionals have more ownership in VSTM or MNKD?

Which has better valuation & earnings, VSTM or MNKD?

Do analysts recommend VSTM or MNKD?

Summary

How does Verastem compare to Zenas BioPharma?

Which has higher earnings & valuation, VSTM or ZBIO?

Do insiders & institutionals hold more shares of VSTM or ZBIO?

Which has more risk and volatility, VSTM or ZBIO?

Does the media prefer VSTM or ZBIO?

Is VSTM or ZBIO more profitable?

Do analysts recommend VSTM or ZBIO?

Summary

How does Verastem compare to OPKO Health?

Does the media refer more to VSTM or OPK?

Do institutionals and insiders hold more shares of VSTM or OPK?

Is VSTM or OPK more profitable?

Which has stronger valuation and earnings, VSTM or OPK?

Do analysts recommend VSTM or OPK?

Which has more volatility and risk, VSTM or OPK?

Summary

How does Verastem compare to Lexicon Pharmaceuticals?

Do institutionals & insiders hold more shares of LXRX or VSTM?

Do analysts rate LXRX or VSTM?

Which has higher earnings and valuation, LXRX or VSTM?

Does the media prefer LXRX or VSTM?

Is LXRX or VSTM more profitable?

Which has more risk and volatility, LXRX or VSTM?

Summary

How does Verastem compare to Geron?

Which has preferable earnings & valuation, GERN or VSTM?

Does the media prefer GERN or VSTM?

Is GERN or VSTM more profitable?

Do analysts rate GERN or VSTM?

Do insiders & institutionals hold more shares of GERN or VSTM?

Which has more volatility and risk, GERN or VSTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM vs. The Competition

Verastem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools